"The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver"...
Human experience of overdose with OLYSIO is limited. There is no specific antidote for overdose with OLYSIO. In the event of an overdose, the patient's clinical status should be observed and the usual supportive measures employed.
There are no specific contraindications to OLYSIO. However, as OLYSIO should always be administered in combination with other antiviral drugs for the treatment of CHC infection, prescribers should consult the complete prescribing information for these drugs for a description of contraindications.
If OLYSIO is administered with Peg-IFN-alfa and RBV, the contraindications for use of Peg-IFN-alfa and RBV also apply to this combination regimen. Refer to the prescribing information for Peg-IFN-alfa and RBV for a list of all contraindications.
Last reviewed on RxList: 4/23/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Olysio Information
Report Problems to the Food and Drug Administration
Find out what women really need.